Carcinoembryonic antigen surge in metastatic colorectal cancer patients responding to irinotecan combination chemotherapy

被引：11

作者：

An, Xin ^{[1
,2
]}

Ding, Pei-Rong ^{[1
,3
]}

Xiang, Xiao-Juan ^{[1
,2
]}

Wang, Zhi-Qiang ^{[1
,2
]}

Wang, Feng-Hua ^{[1
,2
]}

Feng, Fen ^{[1
,2
]}

Jiang, Wen-Qi ^{[1
,2
]}

He, You-Jian ^{[1
,2
]}

Xu, Rui-Hua ^{[1
]}

Li, Yu-Hong ^{[1
,2
]}

机构：

[1] State Key Lab Oncol S China, Guangzhou, Guangdong, Peoples R China

[2] Sun Yat Sen Univ, Ctr Canc, Dept Med Oncol, Guangzhou 510275, Guangdong, Peoples R China

[3] Sun Yat Sen Univ, Ctr Canc, Dept Colorectal Surg, Guangzhou, Guangdong, Peoples R China

来源：

BIOMARKERS | 2010年 / 15卷 / 03期

关键词：

Carcinoembryonic antigen surge; chemotherapy; irinotecan; metastatic colorectal cancer; FOLINIC ACID; COLON-CANCER; TUMOR-MARKER; CEA; EXPRESSION; 5-FLUOROURACIL; OXALIPLATIN; THERAPY; CELLS; INCREASE;

D O I：

10.3109/13547500903477377

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

Methods: We retrospectively reviewed 132 patients with metastatic colorectal cancer treated with irinotecan-based chemotherapy. Incidence of a CEA surge and chemotherapy efficacy were investigated. Results: Eleven of 99 eligible patients (11.1%) had CEA surges. None of the 11 patients showed progressive disease (four had a partial response, seven had stable disease). Conclusion: A CEA surge can be induced by irinotecan-based chemotherapy. An early increase in CEA after irinotecan-based chemotherapy does not usually indicate progression of disease and failure of therapy, and should not lead to a change of chemotherapy.

引用

页码：243 / 248

页数：6

共 20 条

[1] Chemotherapy-induced carcinoembryonic antigen surge in patients with metastatic colorectal cancer [J].

Ailawadhi, S ;

Sunga, A ;

Rajput, A ;

Yang, GY ;

Smith, J ;

Fakih, M .

ONCOLOGY, 2006, 70 (01) :49-53

[2] Drug-induced increase of carcinoembryonic antigen expression in cancer cells [J].

Aquino, A ;

Formica, V ;

Prete, SP ;

Correale, PP ;

Massara, MC ;

Turriziani, M ;

De Vecchis, L ;

Bonmassar, E .

PHARMACOLOGICAL RESEARCH, 2004, 49 (05) :383-396

[3]

Aquino A, 1998, CLIN CANCER RES, V4, P2473

[4] CARCINOEMBRYONIC ANTIGEN, A HUMAN-TUMOR MARKER, FUNCTIONS AS AN INTERCELLULAR-ADHESION MOLECULE [J].

BENCHIMOL, S ;

FUKS, A ;

JOTHY, S ;

BEAUCHEMIN, N ;

SHIROTA, K ;

STANNERS, CP .

CELL, 1989, 57 (02) :327-334

[5] Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer [J].

Cunningham, D ;

Humblet, Y ;

Siena, S ;

Khayat, D ;

Bleiberg, H ;

Santoro, A ;

Bets, D ;

Mueser, M ;

Harstrick, A ;

Verslype, C ;

Chau, I ;

Van Cutsem, E .

NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (04) :337-345

[6] CARCINOEMBRYONIC ANTIGEN [J].

FLETCHER, RH .

ANNALS OF INTERNAL MEDICINE, 1986, 104 (01) :66-73

[7] CEA and CA 19-9 measurement as a monitoring parameter in metastatic colorectal cancer (CRC) under palliative first-line chemotherapy with weekly 24-hour infusion of high-dose 5-fluorouracil (5-FU) and folinic acid (FA) [J].

Hanke, B ;

Riedel, C ;

Lampert, S ;

Happich, K ;

Martus, P ;

Parsch, H ;

Himmler, B ;

Hohenberger, W ;

Hahn, EG ;

Wein, A .

ANNALS OF ONCOLOGY, 2001, 12 (02) :221-226

[8] Cancer statistics, 2005 [J].

Jemal, A ;

Murray, T ;

Ward, E ;

Samuels, A ;

Tiwari, RC ;

Ghafoor, A ;

Feuer, EJ ;

Thun, MJ .

CA-A CANCER JOURNAL FOR CLINICIANS, 2005, 55 (01) :10-30

[9]

Li Yu-Hong, 2009, Ai Zheng, V28, P939

[10] ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer [J].

Locker, Gershon Y. ;

Hamilton, Stanley ;

Harris, Jules ;

Jessup, John M. ;

Kemeny, Nancy ;

Macdonald, John S. ;

Somerfield, Mark R. ;

Hayes, Daniel F. ;

Bast, Robert C., Jr. .

JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (33) :5313-5327

← 1 2 →